MyAV·¶

XClose

Joint Research Office

Home
Menu

Major MyAV·¶H investment in research and training to benefit staff and patients

4 April 2022

A MyAV·¶H investment of £20 million will fund training for healthcare assistants and major new research facilities which will benefit patient care.

The investment will be made through grants to MyAV·¶ and MyAV·¶H Charity and will improve clinical outcomes, patient safety and patient experience and support the workforce at MyAV·¶H through developing new technologies for implementation in the NHS.

MyAV·¶H has a close strategic partnership with MyAV·¶ in research. MyAV·¶ hosts clinical research leads and typically takes on the responsibility of sponsoring research studies.

Grant money will pay for new cancer research facilities and an expansion of MyAV·¶H and MyAV·¶â€™s digital research capabilities. In addition, it will pay for the training of healthcare assistants to registered nurse status.

The investment in research will strengthen MyAV·¶H’s position as a research hospital. It will be spent over the next five years to 2027, and major new infrastructure and projects are as follows.

Cancer Clinical Research Facility

Grant money will pay for a new Cancer Clinical Research Facility (CRF) with dedicated research beds for inpatient stays co-located with existing inpatient beds and nursing support.

The Cancer CRF will increase capacity for cancer research at MyAV·¶H including ‘first in human’ trials.

Investment will also progress leading research at MyAV·¶H and MyAV·¶ in the use of advanced imaging and blood biomarkers to develop and evaluate new tests to detect cancers or their MyAV·¶ much earlier, in order to dramatically improve chances of survival.

Advanced Therapy Centre

A new Advanced Therapy Centre will aid the development of advanced cell and gene therapies for patients with neurological disorders and other conditions.

At the centre MyAV·¶H and MyAV·¶ researchers will determine if potentially revolutionary new therapies being developed for motor neurone disease, Parkinson’s disease and multiple sclerosis deliver better outcomes for patients with these conditions.

Data and digital

The pandemic illustrated how the safe use of routine patient data helped speed up insights into better understanding the disease, who was at risk, and aided the rapid development of new treatments.

This investment will enable MyAV·¶H and MyAV·¶ to extend this work to many other disease areas, safely using data at scale. Grant money will be used to create a digital innovation hub within MyAV·¶H to show how data can be used to drive forward care.

Preventing ill health

The investment will enable MyAV·¶H to be at the forefront of using genomics to predict and prevent disease. Grant money will enable significant expansion of cutting-edge research at MyAV·¶H and MyAV·¶ into links between genes, the environment, health and disease.

Investment in staff

Grant money will support NHS staff who lead or support research, and will fully fund 55 healthcare assistants and nursing associates to train as registered nurses over the next five years

MyAV·¶H Chief Executive David Probert said: “I am delighted we can announce this investment today which will be game changing in terms of the research we are able to do, and which will directly support the training and development of our workforce. Our patients stand to benefit hugely from both.â€

Professor Bryan Williams, Director of Research, MyAV·¶H, said: “Investment in research like this directly contributes to improvements in clinical care. This is through new and innovative approaches to care, and indeed, in some cases, the treatments that will be enabled by this investment will be treatments of last resort that have the potential to be life-saving or life changing.â€

Professor David Lomas, Vice-Provost Health at MyAV·¶, said: “This investment is testament to the importance of the partnership between MyAV·¶H and the world-leading clinical research carried out at MyAV·¶, which is helping transform patient lives.â€